Evaluation of Hemogram Indices of Children with Epilepsy Receiving Short-Term Levetiracetam Treatment

Basit Öğe Kaydı
dc.authoridKasap, Tolga/0000-0002-1046-7638
dc.contributor.authorCokyaman, Turgay
dc.contributor.authorKasap, Tolga
dc.date.accessioned2025-01-27T20:35:06Z
dc.date.available2025-01-27T20:35:06Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: The effects of levetiracetam on hemogram parameters are comparable with other antiepileptics. This study aimed to compare the effects of levetirace-tam monotherapy for at least 6 months on hemogram indices with valproic acid. Methods: Cases aged 6-18 years who received levetiracetam (n = 42) or valproic acid (n = 46) monotherapy for at least 6 months were randomly selected. The hemogram data closest to the study cutoff point of those who completed a minimum of 6 months of monotherapy were recorded. White blood cell count, neutrophil count, lymphocyte count, red blood cell distribution width, platelet, mean platelet volume, neutr ophil /lymp hocyt e ratio, red cell distribution width to platelet ratio, mean platelet volume to platelet ratio, platelet to lymphocyte ratio, and lymphopenic case rates were compared between levetiracetam and valproic acid groups. Results: The number of lymphopenic cases (absolute lymphocyte < 1500/mm3) was higher in the levetiracetam group (n = 8) compared to the valproic acid group (n = 3) (log-rank analysis, P = .002). The lymphocyte count was found to be lower in the levetiracetam group compared to the valproic acid group (mean 2274 +/- 964 vs. 2523 +/- 653, P = .153). The neutr ophil /lymp hocyt e ratio (mean 2.4 +/- 2.3 vs. 1.6 +/- 1.3, P = .042) and platelet to lymphocyte ratio indices (mean 141 +/- 63 vs. 105 +/- 40, P = .002) associated with lymphocyte count were significantly higher in the levetiracetam group. Conclusion: Levetiracetam has more lymphopenia side effects than valproic acid. Viral, fungal, and opportunistic infections that develop during levetiracetam treatment may be due to lymphopenia. In cases deemed necessary, absolute lymphocyte count, lymphocyte subgroup analysis, and serum immunoglobulin levels should be reviewed.
dc.identifier.doi10.5152/ArchEpilepsy.2022.221630
dc.identifier.endpage119
dc.identifier.issn2792-0550
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85163143302
dc.identifier.scopusqualityQ4
dc.identifier.startpage113
dc.identifier.trdizinid1131857
dc.identifier.urihttps://doi.org/10.5152/ArchEpilepsy.2022.221630
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1131857
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23568
dc.identifier.volume28
dc.identifier.wosWOS:000869569800003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherAves
dc.relation.ispartofArchives of Epilepsy
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectLevetiracetam
dc.subjectleukocytes
dc.subjectlymphocyte
dc.subjectlymphopenia
dc.subjectplatelet
dc.titleEvaluation of Hemogram Indices of Children with Epilepsy Receiving Short-Term Levetiracetam Treatment
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu